Efgartigimod Alfa Injection bulk supplier for pharma manufacturers

Efgartigimod Alfa Injection Suppliers & Bulk Manufacturers

Available Forms: Vial (IV infusion); vial or pre-filled syringe (subcutaneous)

Available Strengths: 400 mg/20 mL (IV); 1008 mg/11,200 U hyaluronidase per 5.6 mL (SC)

Pack Sizes: Single vial or syringe

Reference Brands: Vyvgart, Vyvgart Hytrulo (argenx)

Efgartigimod alfa (Vyvgart, argenx) lowers harmful IgG antibodies by blocking the FcRn receptor. It is used for generalised myasthenia gravis and, as the subcutaneous Vyvgart Hytrulo, for CIDP. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Efgartigimod Alfa Injection? List it or send an offer →

Product Description:

Efgartigimod alfa is an antibody fragment that blocks the neonatal Fc receptor (FcRn). FcRn normally rescues IgG antibodies from breakdown, keeping them in the blood for weeks. When it is blocked, IgG levels, including the autoantibodies that attack nerve and muscle, fall by more than half within days.

It is approved for generalised myasthenia gravis in adults with anti-acetylcholine-receptor antibodies, given in cycles of four weekly doses, with further cycles based on symptoms. A subcutaneous form combined with hyaluronidase (Vyvgart Hytrulo) is also approved for chronic inflammatory demyelinating polyneuropathy (CIDP), and a pre-filled syringe allows self-injection.

Sourcing notes. Efgartigimod is patented and there is no biosimilar. Because treatment is given in cycles, buyers should plan quantities per cycle and per patient. It is a cold-chain product. Rozanolixizumab, another FcRn blocker, is also listed on PharmaTradz.

How Efgartigimod Alfa Injection is supplied today, and licensing ahead of patent expiry

Efgartigimod Alfa Injection is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Efgartigimod Alfa Injection, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Efgartigimod Alfa Injection supply →

Back to Listing